Results of a Clinical Study of Pevonedistat (Pev),a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

被引：10
|
作者：
Swords, Ronan T. [1 ]
Coutre, Steven [2 ]
Maris, Michael B. [3 ]
Zeidner, Joshua F. [4 ]
Foran, James M. [5 ]
Cruz, Jose C. [6 ]
Erba, Harry P. [7 ,8 ]
Berdeja, Jesus G. [9 ]
Tam, Wayne [10 ]
Vardhanabhuti, Saran [11 ]
Dobler, Iwona [11 ]
Faessel, Helene M. [12 ]
Dash, Ajeeta B. [13 ]
Sedarati, Farhad [14 ]
Dezube, Bruce J. [14 ]
Savona, Michael R. [15 ,16 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol Oncol, Miami, FL USA
[2] Stanford Univ, Med, Stanford, CA USA
[3] Colorado Blood Canc Inst, Denver, CO USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[5] Mayo Clin, Jacksonville, FL USA
[6] Texas Transplant Inst, Bone Marrow Transplant, San Antonio, TX USA
[7] Univ Alabama Birmingham, Div Hematol, Internal Med, Birmingham, AL USA
[8] Univ Alabama Birmingham, Div Oncol, Internal Med, Birmingham, AL USA
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Weill Cornell Med Ctr, Pathol & Lab Med, New York, NY USA
[11] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Biostatist, Cambridge, MA USA
[12] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Quantitat Clin Pharmacol, Cambridge, MA USA
[13] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Translat & Biomarker Res, Cambridge, MA USA
[14] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
[15] Vanderbilt Univ Sch Med, Internal Med, Nashville, TN USA
[16] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.98.98
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
98
引用
收藏
页数：8
相关论文
共 44 条
  • [1] Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
    Swords, Ronan T.
    Coutre, Steven
    Maris, Michael B.
    Zeidner, Joshua F.
    Foran, James M.
    Cruz, Jose
    Erba, Harry P.
    Berdeja, Jesus G.
    Tam, Wayne
    Vardhanabhuti, Saran
    Pawlikowska-Dobler, Iwona
    Faessel, Helene M.
    Dash, Ajeeta B.
    Sedarati, Farhad
    Dezube, Bruce J.
    Faller, Douglas V.
    Savona, Michael R.
    BLOOD, 2018, 131 (13) : 1415 - 1424
  • [2] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
    R T Swords
    J Watts
    H P Erba
    J K Altman
    M Maris
    F Anwer
    Z Hua
    H Stein
    H Faessel
    F Sedarati
    B J Dezube
    F J Giles
    B C Medeiros
    D J DeAngelo
    Blood Cancer Journal, 2017, 7 : e520 - e520
  • [3] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
    Swords, R. T.
    Watts, J.
    Erba, H. P.
    Altman, J. K.
    Maris, M.
    Anwer, F.
    Hua, Z.
    Stein, H.
    Faessel, H.
    Sedarati, F.
    Dezube, B. J.
    Giles, F. J.
    Medeiros, B. C.
    DeAngelo, D. J.
    BLOOD CANCER JOURNAL, 2017, 7 : e520 - e520
  • [4] PEVONEDISTAT, A FIRST-IN-CLASS NEDD8-ACTIVATING ENZYME INHIBITOR, IS A POTENT INHIBITOR OF HEPATITIS B VIRUS
    Sekiba, Kazuma
    Otsuka, Motoyuki
    Koike, Kazuhiko
    GASTROENTEROLOGY, 2019, 156 (06) : S1194 - S1194
  • [5] Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Bixby, Dale L.
    Altman, Jessica K.
    Maris, Michael
    Hua, Zhaowei
    Blakemore, Stephen J.
    Faessel, Helene
    Sedarati, Farhad
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 534 - 543
  • [6] THE FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), MLN4924, INDUCES STABLE DISEASE REGRESSION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA (AML)
    Carew, J.
    Swords, R.
    Kelly, K.
    Smith, P.
    Garnsey, J.
    Mahalingam, D.
    Medina, E.
    O'Dwyer, M.
    Oberheu, K.
    Nawrocki, S.
    Giles, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 183 - 183
  • [7] Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVA51 oncolytic virotherapy
    Wong, Boaz
    Bergeron, Anabel
    Maznyi, Glib
    Ng, Kristy
    Jirovec, Anna
    Birdi, Harsimrat K.
    Serrano, Daniel
    Spinelli, Marcus
    Thomson, Max
    Taha, Zaid
    Alwithenani, Akram
    Chen, Andrew
    Lorimer, Ian
    Vanderhyden, Barbara
    Arulanandam, Rozanne
    Diallo, Jean -Simon
    MOLECULAR THERAPY, 2023, 31 (11) : 3176 - 3192
  • [8] Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study (vol 169, pg 534, 2015)
    Swords, R. T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (02) : 294 - 294
  • [9] Metabolism and Disposition of [14C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors
    Bolleddula, Jayaprakasam
    Chen, Hao
    Cohen, Lawrence
    Zhou, Xiaofei
    Pusalkar, Sandeepraj
    Berger, Allison
    Sedarati, Farhad
    Venkatakrishnan, Karthik
    Chowdhury, Swapan K.
    DRUG METABOLISM AND DISPOSITION, 2022, 50 (07) : 989 - 997
  • [10] MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study.
    Bhatia, S.
    Hamid, O.
    Pavlick, A. C.
    Mulligan, G.
    Smith, P. G.
    Pickard, M. D.
    Shultz, M.
    Walker, R. M.
    Dezube, B.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345